Has anyone tried CB-01-03 aka Clascoterone? 3/9/2026
Clascoterone, a topical anti-androgen, is generating interest for potentially fewer systemic side effects. Users are curious about its effectiveness and details like concentration and duration of use.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity I Get Side-Effects from Anti-Androgens
Someone looking for solutions to their hair loss, who has tried and failed to tolerate anti-androgen treatments such as finasteride, CB-03-01, RU58841, and Eucapil. The user is seeking advice and understanding of their extreme sensitivity to these treatments.
community What has the evidence been on side effects with CB?
Clascoterone (CB) shows an excellent safety profile with no serious side effects, but its effectiveness may decline after six months, making it more suitable as an adjunct treatment with finasteride and minoxidil rather than a standalone solution. Some argue it could be better than finasteride due to its protection against testosterone, but its long-term efficacy remains debated.
community Chat is this real? Compound called clascoterone
Clascoterone shows promising results for hair regrowth in men with androgenetic alopecia, with potential FDA approval by 2026. It acts as a topical androgen receptor blocker, offering a new treatment option with minimal side effects compared to existing treatments like finasteride.
community What do we currently know about clascoterone?
Clascoterone is seen as a promising topical treatment for hair loss, similar to finasteride but without side effects, though concerns exist about its long-term effectiveness. Other treatments discussed include topical minoxidil, ketoconazole, microneedling, and oral options like dutasteride and minoxidil.
community Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results
Clascoterone 5% solution shows strong potential for hair growth, offering a new treatment for alopecia with minimal side effects. It blocks androgen receptors locally and may be available by late 2026 or early 2027.
Related Research
6 / 6 results
research Biological Profile of Cortexolone 17a-Propionate (CB-03-01), a New Topical and Peripherally Selective Androgen Antagonist
This study found that cortexolone 17α-propionate showed strong topical antiandrogenic activity, outperforming progesterone and several known antiandrogens, but lacked systemic antiandrogenic effects in animal models.
research Differential diagnosis of trichotillomania by trichoscopy
Azathioprine may help with severe hair loss, a new topical treatment could counteract hair thinning, and trichoscopy can diagnose hair-pulling disorder effectively.
research Cortexolone 17a-propionate: A new antiandrogen acting on hair dermal papilla cells for the treatment of androgenic alopecia
Cortexolone 17a-propionate may be an effective new treatment for hair loss.
research BRIDGING THE GAP IN ACNE MANAGEMENT: A NARRATIVE REVIEW OF CURRENT THERAPIES AND THE EMERGENCE OF CLASCOTERONE
This source describes clascoterone, a new topical treatment for acne vulgaris that blocks androgen receptors to reduce sebaceous gland activity and inflammation, offering a lower risk of systemic side effects compared to oral treatments.
research Androgens and acne: perspectives on clascoterone, the first topical androgen receptor antagonist
This review highlights that clascoterone, a newly FDA-approved topical androgen antagonist, effectively reduces both non-inflammatory and inflammatory acne lesions with no systemic effects, making it a promising new option for acne treatment in both male and female patients.
research Androgen Receptor Inhibitors in the Treatment of Acne Vulgaris: Efficacy and Safety Profiles of Clascoterone 1% Cream
This review discusses the clinical trials of clascoterone 1% cream for acne vulgaris and reports no new results; the authors highlight its novel role as a topical antiandrogen.